NCT06660563 - A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 22, 2024

Primary Completion Date

September 21, 2026

Study Completion Date

September 21, 2026

Conditions

Lymphoma, Non-Hodgkin

Interventions

DRUG

JNJ-80948543

JNJ-80948543 will be administered as subcutaneous (SC) or intravenous (IV) injection.

DRUG

JNJ-75348780

JNJ-75348780 will be administered as SC injection.

Trial Locations (11)

100

RECRUITING

National Taiwan University Hospital, Taipei

2109

RECRUITING

Macquarie University Hospital, North Ryde

2139

RECRUITING

Concord Hospital, Concord

3065

RECRUITING

St Vincents Hospital Melbourne, Fitzroy

28007

RECRUITING

Hosp. Gral. Univ. Gregorio Maranon, Madrid

28041

RECRUITING

Hosp. Univ. 12 de Octubre, Madrid

40447

RECRUITING

China Medical University Hospital, Taichung

08035

RECRUITING

Hosp Univ Vall D Hebron, Barcelona

08036

RECRUITING

Hosp. Clinic de Barcelona, Barcelona

08908

RECRUITING

Inst. Cat. Doncologia-H Duran I Reynals, L'Hospitalet de Llobregat

Le1 5ww

RECRUITING

University Hospitals Of Leicester Nhs Trust, Leicester

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY